Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up - European Society for Medical Oncology (ESMO)

Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders predominating in the elderly, with a median age at diagnosis of ~70 years. This ESMO Clinical Practice Guideline provides key recommendations for managing myelodysplastic syndromes. It covers diagnosis, classification, staging and risk assessment of myelodysplastic syndromes. Treatment recommendations for lower- and higher-risk myelodysplastic syndromes are also provided. All recommendations were compiled by a multidisciplinary group of experts. Recommendations are based on available scientific data and the authors’ expert opinion.


Read full guideline